Asoprisnil

Asoprisnil
	File:Asoprisnil.png
Systematic (IUPAC) name
	rel-4-[(8R,11S,13R,14R,17R)-17-Methoxy-17- (methoxymethyl)-13-methyl-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro- 1H-cyclopenta[a]phenanthren-11-yl]benzaldehyde oxime
Identifiers
CAS Number	199396-76-4
ATC code	none
PubChem	CID 9577221
ChemSpider	7851660
Chemical data
Formula	C28H35NO4
Molar mass	449.582 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Asoprisnil (J867) is an investigational selective progesterone receptor modulator developed by Schering and TAP Pharmaceutical Products, tested for treatment of progesterone sensitive myomata.^[1]

In 2005, Phase III trials were discontinued due to endometrial changes in patients. It is uncertain whether asoprisnil will be marketed.^[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

40px	This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. v d e

↑ DeManno D, Elger W, Garg R; et al. (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids. 68 (10-13): 1019–32. doi:10.1016/j.steroids.2003.09.008. PMID 14667995.
↑ Schering Interim Report Q1-3 2005